Iron deficiency anemia.
Conditions
Interventions
Intervention 1: Intervention group: In one group of patients, 150-200 mg of elemental iron is given daily (in the form of ferrofort tablets of Abidi Pharmaceutical Company twice a day). Intervention 2
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
15 Years to 50 Years
Inclusion criteria
Inclusion criteria: Age = 15 years and less than 50 years outpatients Women with iron deficiency with ferritin less than 30 micrograms per liter No pregnancy No breastfeeding right now Absence of comorbidities (ckd, DM, IHD, etc.) Lack of known history of inflammatory bowel disease Lack of known history of celiac disease No known history or thalassemia No known hereditary bleeding disorder Do not take multivitamin and mineral supplements (35 mg or more of essential iron per day) in the 2 weeks prior to randomization. No allergy to oral iron Lack of intravenous iron therapy in the last 12 weeks Do not receive anticoagulants (eg warfarin, apixaban, debigatran, adoxaban, Riveroxban) Lack of creatinine clearance less than 30 ml per minute Lack of hemoglobin less than 80 g / l with active bleeding No chemotherapy planned for the next 12 weeks. No surgery is scheduled for the next 12 weeks.
Exclusion criteria
Exclusion criteria: Intolerance or non-response to oral iron gluconate, sulfate or fumarate in the last 12 weeks Received frequent anemia treatments and are resistant to anemia treatment. Dissatisfaction to participate in the study or lack of cooperation and consent to continue treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemoglobin. Timepoint: The beginning of the study, two weeks and a month and a half after the intervention. Method of measurement: Using the device.;Ferritin. Timepoint: At the beginning of the study and one and a half months after the intervention. Method of measurement: Using the device.;Retic COUNT. Timepoint: First and two weeks after the intervention. Method of measurement: Using the device.;Serum iron levels. Timepoint: At the beginning of the study and one and a half months after the intervention. Method of measurement: Using the device.;TIBC. Timepoint: At the beginning of the study and one and a half months after the intervention. Method of measurement: Using the device. | — |
Secondary
| Measure | Time frame |
|---|---|
| General clinical symptoms(weakness, fatigue, drowsiness, restlessness, anxiety, etc.). Timepoint: at the beginning and end of the study. Method of measurement: check list.;Side effects during the study (nausea and vomiting, black stools / heartburn, etc.). Timepoint: during the study. Method of measurement: check list. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNegar Gheytassi
Arak University of Medical Sciences
Outcome results
None listed